Filing Flows › BioAge Labs (BIOA) › Q3 2026
BioAge Labs (BIOA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
BioAge Labs (BIOA) reported revenue of $298K for the third quarter 2026 (Q3 2026), -85% from a year earlier and -88% from the quarter before.
BioAge Labs, Q3 2026: revenue $298K (-86% year over year), net loss $33.5M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $298K | -88% | -85% |
| Operating profit | −$37.4M | — | — |
| Net earnings | −$33.5M | — | — |
| Operating cash flow | −$31.0M | — | — |
What changed
Revenue was $298K in Q3 2026, down 85% year over year and down 88% from the previous quarter.
Operating costs exceeded revenue by $37.4M, an operating margin of -12554.0%. Total costs grew 50% against a revenue fall of 85%. The fastest-growing cost line was Research & development (+63%). The quarter ended with a net loss of $33.5M, wider than the previous quarter's $26.1M loss.
Operating cash flow was −$31.0M. Non-cash charges added back $100K of depreciation and $4.6M of share-based compensation. Working capital and other items used $2.2M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$31.0M.
Questions
What was BioAge Labs' revenue in the third quarter 2026?
BioAge Labs (BIOA) reported revenue of $298K for the third quarter 2026 (Q3 2026), -85% from a year earlier and -88% from the quarter before.
Source: BioAge Labs 10-Q on SEC EDGAR.